Efficacy of telavancin in a murine model of pneumonia induced by methicillin-susceptible Staphylococcus aureus

Journal of Antimicrobial Chemotherapy

Volumn 61, Issue 1, 2008, Pages 169-172

  Hegde, Sharath S ^a   Reyes, Noe ^a   Skinner, Robert ^a   Difuntorum, Stacey ^a  

^a THERAVANCE INC   (United States)

Author keywords

Lipoglycopeptide; Mouse; MRSA; Nafcillin; Vancomycin

Indexed keywords

LINEZOLID; METICILLIN; NAFCILLIN; TELAVANCIN; VANCOMYCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBIOTIC SENSITIVITY; AREA UNDER THE CURVE; ARTICLE; BACTERIAL COUNT; BACTERIAL PNEUMONIA; BACTERICIDAL ACTIVITY; COLONY FORMING UNIT; CONTROLLED STUDY; DISEASE MODEL; DRUG EFFICACY; FEMALE; INOCULATION; LUNG HOMOGENATE; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NEUTROPENIA; NONHUMAN; STAPHYLOCOCCUS AUREUS; TREATMENT OUTCOME;

AMINOGLYCOSIDES; ANIMALS; ANTI-BACTERIAL AGENTS; FEMALE; METHICILLIN RESISTANCE; MICE; MICE, INBRED BALB C; PNEUMONIA, STAPHYLOCOCCAL; STAPHYLOCOCCUS AUREUS;

EID: 37549017665     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkm417     Document Type: Article

References (12)

1. American Thoracic Society and Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 2005; 171: 388-416.
2. National Nosocomial Infections Surveillance System. National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2004, issued October 2004. Am J Infect Control 2004; 32: 470-85.
3. Gonzalez C, Rubio M, Romero-Vivas J et al. Bacteremic pneumonia due to Staphylococcus aureus: A comparison of disease caused by methicillin-resistant and methicillin-susceptible organisms. Clin Infect Dis 1999; 29: 1171-7.
4. Rubinstein E, Cammarata S, Oliphant T et al. Linezolid (PNU-100766) versus vancomycin in the treatment of hospitalized patients with nosocomial pneumonia: A randomized, double-blind, multicenter study. Clin Infect Dis 2001; 32: 402-12.
5. Higgins DL, Chang R, Debabov DV et al. Telavancin, a multi-functional lipoglycopeptide, disrupts both cell wall synthesis and cell membrane integrity in methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2005; 49: 1127-34.
6. Pace JL, Krause K, Johnston D et al. In vitro activity of TD-6424 against Staphylococcus aureus. Antimicrob Agents Chemother 2003; 47: 3602-4.
7. Reyes N, Skinner R, Kaniga K et al. Efficacy of telavancin (TD-6424), a rapidly bactericidal lipoglycopeptide with multiple mechanisms of action, in a murine model of pneumonia induced by methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2005; 49: 4344-6.
8. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing: Sixteenth Informational Supplement M100-S16. CLSI, Wayne, PA, USA, 2006.
9. Clinical and Laboratory Standards Institute. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically - Sixth Edition: Approved Standard M7-A6. CLSI, Wayne, PA, USA, 2006.
10. National Committee for Clinical Laboratory Standards. Methods for Determining Bactericidal Activity of Antimicrobial Agents: Approved Guideline M26-A. NCCLS, Wayne, PA, USA, 1999.
11. Slatter JG, Adams LA, Bush EC et al. Pharmacokinetics, toxico-kinetics, distribution, metabolism and excretion of linezolid in mouse, rat and dog. Xenobiotica 2002; 32: 907-24.
12. Draghi DC, Benton BM, Jones ME et al. Baseline anti-staphylococcal profile of telavancin: Results of the 2004-2005 US and Europe surveillance initiative based on specimen source. Presented at the Tenth Western Pacific Congress on Chemotherapy and Infectious Diseases, Fukuoka, Japan, 2006. Poster P2-033.